Vaximm AG Shortens Exclusivity Period with BCM Europe to Enhance Licensing Negotiations

Vaximm AG Updates Term Sheet with BCM Europe

On December 2, 2025, OSR Holdings, Inc. (NASDAQ: OSRH) announced significant changes regarding the non-binding term sheet initially established between its subsidiary, Vaximm AG, and BCM Europe AG (BCME). The newly revised agreement will reduce the exclusivity period from six months to just three months, which indicates the strong alignment and confidence both companies share in moving forward with a comprehensive licensing deal for VXM01, a pioneering orally administered cancer immunotherapy developed by Vaximm.

This revised timeline suggests that Vaximm and BCME are aiming to finalize their definitive agreement swiftly, likely due to BCME's proven track record in efficiently managing financing and the necessary infrastructure that is critical for potential global licensing to a major pharmaceutical partner. BCME’s capacity for streamlining the due diligence processes also contributes to energizing this partnership.

The financial conditions of the new agreement have remained stable, including a substantial upfront payment of $20 million to Vaximm, alongside potential milestone payments totaling up to $815 million. This sum will cover different stages of clinical, regulatory, and commercial progress, along with a mechanism to enable BCME to earn commercial royalties from any future partnerships established through this licensing agreement. The terms also include a unique blockchain-based royalty participation model, which utilizes